Attached files
| file | filename |
|---|---|
| EX-99.4 - EX-99.4 - Tempest Therapeutics, Inc. | d138850dex994.htm |
| EX-99.1 - EX-99.1 - Tempest Therapeutics, Inc. | d138850dex991.htm |
| EX-99.5 - EX-99.5 - Tempest Therapeutics, Inc. | d138850dex995.htm |
| EX-99.2 - EX-99.2 - Tempest Therapeutics, Inc. | d138850dex992.htm |
| EX-99.3 - EX-99.3 - Tempest Therapeutics, Inc. | d138850dex993.htm |
| 8-K - 8-K - Tempest Therapeutics, Inc. | d138850d8k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-228209 and 333-230749 on Form S-3 and Registration Statement Nos. 333-182040, 333-187897, 333-195780, 333-202793, 333-209775, 333-214414, 333-216405, 333-221292, 333-226750, 333-230749, 333-230750, 333-235515, 333-249993, 333-255261, and 333-257727 on Form S-8 of our report dated May 10, 2021, relating to the financial statements of Tempest Therapeutics, Inc. appearing in this Current Report on Form 8-K dated July 16, 2021.
/s/Deloitte & Touche LLP
San Francisco, California
July 16, 2021